Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nuria Kotecki

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Oncology|January 20, 2016
First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease ControlNuria Kotecki, Sandrine Hiret, Pierre-Luc Etienne, et al.
JAMA Oncology|November 2, 2018
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical TrialLillian L Siu, Caroline Even, Ricard Mesía, et al.
European Journal of Cancer (Oxford, England : 1990)|April 25, 2026
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumoursMarie Robert, Nuria Kotecki, Carlos Gomez-Roca, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Oncology|January 20, 2016
First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease ControlNuria Kotecki, Sandrine Hiret, Pierre-Luc Etienne, et al.
JAMA Oncology|November 2, 2018
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical TrialLillian L Siu, Caroline Even, Ricard Mesía, et al.
European Journal of Cancer (Oxford, England : 1990)|April 25, 2026
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumoursMarie Robert, Nuria Kotecki, Carlos Gomez-Roca, et al.
Pageof 4